Last updated: April 24, 2026
What suppliers produce capmatinib hydrochloride API?
Capmatinib hydrochloride is the API used in the marketed MET inhibitor TABRECTA (capmatinib). Public procurement and supply-chain disclosures typically list firms by API-manufacturing role or finishing/packaging in the drug’s commercial supply chain, with multiple sources used to manage volume and regulatory risk.
Practical supplier categories used in capmatinib commercial sourcing
- API manufacturers (capmatinib synthesis and isolation; often GMP-grade API)
- Salt form manufacturers (capmatinib base to capmatinib hydrochloride conversion and crystallization)
- Commercial packers / drug product manufacturers (not API suppliers, but they can control supply terms if vertically integrated)
Which supplier types are most relevant for sourcing capmatinib hydrochloride?
For capmatinib hydrochloride, buyers generally choose among these supply routes:
| Sourcing route |
What you buy |
Typical advantage |
Typical constraint |
| API (capmatinib hydrochloride) |
Salt-form API with CoA and full GMP dossier |
Faster qualification vs salt conversion |
Higher cost than outsourcing conversion |
| Capmatinib base + salt conversion |
Base API plus conversion to HCl salt |
Lower upstream cost in some tenders |
Requires stable conversion process validation |
| Intermediate supply (for in-house conversion) |
Key intermediates for synthesis |
Control over supply continuity |
Requires process development and regulatory work |
Who are the common global suppliers used for capmatinib commercial supply?
The market uses a multi-supplier model for on-patent and lifecycle-stage coverage. In practice, the same API manufacturers that supply MET inhibitors also list capmatinib in capability catalogs, subject to customer qualification and regulatory acceptance.
Because capmatinib hydrochloride is not a bulk commodity, supplier selection is driven by:
- Regulatory status (DMF/ASMF availability, inspection history, site capability)
- Salt-form control (polymorph/crystal form control for the hydrochloride)
- Batch consistency (impurity profile control, especially for kinase inhibitor scaffolds)
What procurement-ready supplier signals should you screen for (capmatinib-specific)?
When vetting suppliers for capmatinib hydrochloride, buyers typically request documents that validate salt form and impurity control:
| Supplier proof point |
What to request |
Why it matters for capmatinib HCl |
| Salt-form specification |
HCl salt identification and acceptance criteria |
Avoids wrong crystal form / solubility drift |
| Impurity profile |
Impurity list with limits, re-test times |
Kinase inhibitors are impurity-sensitive |
| Analytical package |
COA with HPLC/UPLC, water content, residual solvents |
Needed for batch release and comparability |
| Regulatory dossier |
DMF/ASMF references for the site |
Enables rapid onboarding for commercial supply |
How do buyers typically qualify capmatinib hydrochloride suppliers?
Qualification commonly follows this sequencing:
- Document screen: GMP certificate, CoA sample, impurity table, salt identification methods.
- Regulatory screen: DMF/ASMF linkage to the target jurisdiction.
- Technical screen: stability under intended storage, impurity control across at least 3 consecutive batches.
- Commercial screen: lead time, allocation policy, change control commitments (process, site, analytical method).
Market realities that affect capmatinib hydrochloride sourcing
- HCl salt conversion can create variability if the crystallization envelope differs between suppliers.
- Scale-up for capmatinib synthesis is chemistry constrained, so only a subset of CMOs can reliably deliver at commercial volumes.
- Inspection and dossier status are gating items because buyers often need regulatory traceability rather than just analytical compliance.
What should you expect in supplier offers for capmatinib hydrochloride?
Common offer structures include:
- API supply under a master supply agreement with periodic allocation adjustments
- Change control clauses requiring notification for impurity-spec or process changes
- Conformity to specific pharmacopoeial tests and internal methods for salt identity
Actionable supplier-selection short list (by procurement readiness)
Because capmatinib hydrochloride supply is regulated-dossier driven, the best-fit vendors are typically those that can meet all three procurement anchors simultaneously:
- GMP API supply with salt-form confirmation
- Traceable regulatory dossier support (DMF/ASMF)
- Demonstrated batch-to-batch impurity consistency
Key Takeaways
- Capmatinib hydrochloride is sourced through API manufacturers, salt-form conversion capability, and drug-product supply chain partners.
- Supplier qualification for capmatinib is dominated by salt-form control, impurity profile stability, and regulatory dossier linkage.
- The fastest path to procurement-ready supply is vendors that can deliver GMP capmatinib hydrochloride with a complete analytical package and DMF/ASMF support.
FAQs
1) Is capmatinib hydrochloride typically purchased as the salt or converted in-house?
Most commercial buyers either purchase salt-form API directly or source capmatinib base and run a controlled salt conversion. Salt-form direct supply is preferred when qualification timelines are tight.
2) What quality attributes matter most for capmatinib hydrochloride?
Salt identity (HCl form), impurity profile limits, residual solvents/water content, and consistent crystallization behavior.
3) How do suppliers demonstrate consistent impurity control for kinase inhibitors?
They provide CoA packages across multiple batches with validated impurity methods and defined acceptance limits tied to the drug substance specification.
4) What role do DMFs/ASMFs play in supplier onboarding?
They provide regulatory traceability for the manufacturing site and process, which accelerates acceptance by downstream manufacturers.
5) What tends to delay sourcing capmatinib hydrochloride?
Salt-form variability, incomplete dossier references, insufficient batch data history, or inability to meet agreed impurity and residuals specifications.
References
[1] U.S. Food and Drug Administration. “Tabrecta (capmatinib) Drug Trials Snapshots.” FDA.
[2] European Medicines Agency (EMA). “Tabrecta: EPAR - Product Information.” EMA.
